1 Parkinsons Disease Drugs Market Overview 1.1 Product Overview and Scope of Parkinsons Disease Drugs 1.2 Parkinsons Disease Drugs Segment by Type 1.2.1 Global Parkinsons Disease Drugs Market Value Comparison by Type (2023-2029) 1.2.2 Clinical 1.2.3 Experiment 1.3 Parkinsons Disease Drugs Segment by Application 1.3.1 Global Parkinsons Disease Drugs Market Value by Application: (2023-2029) 1.3.2 Treament 1.3.3 Prevention 1.4 Global Parkinsons Disease Drugs Market Size Estimates and Forecasts 1.4.1 Global Parkinsons Disease Drugs Revenue 2018-2029 1.4.2 Global Parkinsons Disease Drugs Sales 2018-2029 1.4.3 Global Parkinsons Disease Drugs Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Parkinsons Disease Drugs Market Competition by Manufacturers 2.1 Global Parkinsons Disease Drugs Sales Market Share by Manufacturers (2018-2023) 2.2 Global Parkinsons Disease Drugs Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Parkinsons Disease Drugs Average Price by Manufacturers (2018-2023) 2.4 Global Parkinsons Disease Drugs Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Parkinsons Disease Drugs, Product Type & Application 2.7 Parkinsons Disease Drugs Market Competitive Situation and Trends 2.7.1 Parkinsons Disease Drugs Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Parkinsons Disease Drugs Players Market Share by Revenue 2.7.3 Global Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Parkinsons Disease Drugs Retrospective Market Scenario by Region 3.1 Global Parkinsons Disease Drugs Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Parkinsons Disease Drugs Global Parkinsons Disease Drugs Sales by Region: 2018-2029 3.2.1 Global Parkinsons Disease Drugs Sales by Region: 2018-2023 3.2.2 Global Parkinsons Disease Drugs Sales by Region: 2024-2029 3.3 Global Parkinsons Disease Drugs Global Parkinsons Disease Drugs Revenue by Region: 2018-2029 3.3.1 Global Parkinsons Disease Drugs Revenue by Region: 2018-2023 3.3.2 Global Parkinsons Disease Drugs Revenue by Region: 2024-2029 3.4 North America Parkinsons Disease Drugs Market Facts & Figures by Country 3.4.1 North America Parkinsons Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Parkinsons Disease Drugs Sales by Country (2018-2029) 3.4.3 North America Parkinsons Disease Drugs Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Parkinsons Disease Drugs Market Facts & Figures by Country 3.5.1 Europe Parkinsons Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Parkinsons Disease Drugs Sales by Country (2018-2029) 3.5.3 Europe Parkinsons Disease Drugs Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Parkinsons Disease Drugs Market Facts & Figures by Country 3.6.1 Asia Pacific Parkinsons Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Parkinsons Disease Drugs Sales by Country (2018-2029) 3.6.3 Asia Pacific Parkinsons Disease Drugs Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Parkinsons Disease Drugs Market Facts & Figures by Country 3.7.1 Latin America Parkinsons Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Parkinsons Disease Drugs Sales by Country (2018-2029) 3.7.3 Latin America Parkinsons Disease Drugs Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Parkinsons Disease Drugs Market Facts & Figures by Country 3.8.1 Middle East and Africa Parkinsons Disease Drugs Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Parkinsons Disease Drugs Sales by Country (2018-2029) 3.8.3 Middle East and Africa Parkinsons Disease Drugs Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Parkinsons Disease Drugs Sales by Type (2018-2029) 4.1.1 Global Parkinsons Disease Drugs Sales by Type (2018-2023) 4.1.2 Global Parkinsons Disease Drugs Sales by Type (2024-2029) 4.1.3 Global Parkinsons Disease Drugs Sales Market Share by Type (2018-2029) 4.2 Global Parkinsons Disease Drugs Revenue by Type (2018-2029) 4.2.1 Global Parkinsons Disease Drugs Revenue by Type (2018-2023) 4.2.2 Global Parkinsons Disease Drugs Revenue by Type (2024-2029) 4.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Type (2018-2029) 4.3 Global Parkinsons Disease Drugs Price by Type (2018-2029) 5 Segment by Application 5.1 Global Parkinsons Disease Drugs Sales by Application (2018-2029) 5.1.1 Global Parkinsons Disease Drugs Sales by Application (2018-2023) 5.1.2 Global Parkinsons Disease Drugs Sales by Application (2024-2029) 5.1.3 Global Parkinsons Disease Drugs Sales Market Share by Application (2018-2029) 5.2 Global Parkinsons Disease Drugs Revenue by Application (2018-2029) 5.2.1 Global Parkinsons Disease Drugs Revenue by Application (2018-2023) 5.2.2 Global Parkinsons Disease Drugs Revenue by Application (2024-2029) 5.2.3 Global Parkinsons Disease Drugs Revenue Market Share by Application (2018-2029) 5.3 Global Parkinsons Disease Drugs Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Johnson & Johnson 6.1.1 Johnson & Johnson Corporation Information 6.1.2 Johnson & Johnson Description and Business Overview 6.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Johnson & Johnson Parkinsons Disease Drugs Product Portfolio 6.1.5 Johnson & Johnson Recent Developments/Updates 6.2 Gilead Sciences 6.2.1 Gilead Sciences Corporation Information 6.2.2 Gilead Sciences Description and Business Overview 6.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Gilead Sciences Parkinsons Disease Drugs Product Portfolio 6.2.5 Gilead Sciences Recent Developments/Updates 6.3 Pacira 6.3.1 Pacira Corporation Information 6.3.2 Pacira Description and Business Overview 6.3.3 Pacira Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.3.4 Pacira Parkinsons Disease Drugs Product Portfolio 6.3.5 Pacira Recent Developments/Updates 6.4 Sun Pharmaceutical 6.4.1 Sun Pharmaceutical Corporation Information 6.4.2 Sun Pharmaceutical Description and Business Overview 6.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Sun Pharmaceutical Parkinsons Disease Drugs Product Portfolio 6.4.5 Sun Pharmaceutical Recent Developments/Updates 6.5 Luye Pharma 6.5.1 Luye Pharma Corporation Information 6.5.2 Luye Pharma Description and Business Overview 6.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Luye Pharma Parkinsons Disease Drugs Product Portfolio 6.5.5 Luye Pharma Recent Developments/Updates 6.6 Sigma-Tau Group 6.6.1 Sigma-Tau Group Corporation Information 6.6.2 Sigma-Tau Group Description and Business Overview 6.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.6.4 Sigma-Tau Group Parkinsons Disease Drugs Product Portfolio 6.6.5 Sigma-Tau Group Recent Developments/Updates 6.7 Fudan-Zhangjiang 6.6.1 Fudan-Zhangjiang Corporation Information 6.6.2 Fudan-Zhangjiang Description and Business Overview 6.6.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.4.4 Fudan-Zhangjiang Parkinsons Disease Drugs Product Portfolio 6.7.5 Fudan-Zhangjiang Recent Developments/Updates 6.8 Teva Pharmaceutical 6.8.1 Teva Pharmaceutical Corporation Information 6.8.2 Teva Pharmaceutical Description and Business Overview 6.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.8.4 Teva Pharmaceutical Parkinsons Disease Drugs Product Portfolio 6.8.5 Teva Pharmaceutical Recent Developments/Updates 6.9 CSPC 6.9.1 CSPC Corporation Information 6.9.2 CSPC Description and Business Overview 6.9.3 CSPC Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.9.4 CSPC Parkinsons Disease Drugs Product Portfolio 6.9.5 CSPC Recent Developments/Updates 6.10 Novartis 6.10.1 Novartis Corporation Information 6.10.2 Novartis Description and Business Overview 6.10.3 Novartis Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.10.4 Novartis Parkinsons Disease Drugs Product Portfolio 6.10.5 Novartis Recent Developments/Updates 6.11 Kingond Pharm 6.11.1 Kingond Pharm Corporation Information 6.11.2 Kingond Pharm Parkinsons Disease Drugs Description and Business Overview 6.11.3 Kingond Pharm Parkinsons Disease Drugs Sales, Revenue and Gross Margin (2018-2023) 6.11.4 Kingond Pharm Parkinsons Disease Drugs Product Portfolio 6.11.5 Kingond Pharm Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Parkinsons Disease Drugs Industry Chain Analysis 7.2 Parkinsons Disease Drugs Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Parkinsons Disease Drugs Production Mode & Process 7.4 Parkinsons Disease Drugs Sales and Marketing 7.4.1 Parkinsons Disease Drugs Sales Channels 7.4.2 Parkinsons Disease Drugs Distributors 7.5 Parkinsons Disease Drugs Customers 8 Parkinsons Disease Drugs Market Dynamics 8.1 Parkinsons Disease Drugs Industry Trends 8.2 Parkinsons Disease Drugs Market Drivers 8.3 Parkinsons Disease Drugs Market Challenges 8.4 Parkinsons Disease Drugs Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Parkinsons Disease Drugs Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Parkinsons Disease Drugs Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Parkinsons Disease Drugs Market Competitive Situation by Manufacturers in 2022 Table 4. Global Parkinsons Disease Drugs Sales (K Units) of Key Manufacturers (2018-2023) Table 5. Global Parkinsons Disease Drugs Sales Market Share by Manufacturers (2018-2023) Table 6. Global Parkinsons Disease Drugs Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Parkinsons Disease Drugs Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Parkinsons Disease Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Parkinsons Disease Drugs, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Parkinsons Disease Drugs, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Parkinsons Disease Drugs, Product Type & Application Table 12. Global Key Manufacturers of Parkinsons Disease Drugs, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Parkinsons Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinsons Disease Drugs as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Parkinsons Disease Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Parkinsons Disease Drugs Sales by Region (2018-2023) & (K Units) Table 18. Global Parkinsons Disease Drugs Sales Market Share by Region (2018-2023) Table 19. Global Parkinsons Disease Drugs Sales by Region (2024-2029) & (K Units) Table 20. Global Parkinsons Disease Drugs Sales Market Share by Region (2024-2029) Table 21. Global Parkinsons Disease Drugs Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Parkinsons Disease Drugs Revenue Market Share by Region (2018-2023) Table 23. Global Parkinsons Disease Drugs Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Parkinsons Disease Drugs Revenue Market Share by Region (2024-2029) Table 25. North America Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units) Table 27. North America Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units) Table 28. North America Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units) Table 32. Europe Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units) Table 33. Europe Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Parkinsons Disease Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Parkinsons Disease Drugs Sales by Region (2018-2023) & (K Units) Table 37. Asia Pacific Parkinsons Disease Drugs Sales by Region (2024-2029) & (K Units) Table 38. Asia Pacific Parkinsons Disease Drugs Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Parkinsons Disease Drugs Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units) Table 42. Latin America Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units) Table 43. Latin America Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Parkinsons Disease Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Parkinsons Disease Drugs Sales by Country (2018-2023) & (K Units) Table 47. Middle East & Africa Parkinsons Disease Drugs Sales by Country (2024-2029) & (K Units) Table 48. Middle East & Africa Parkinsons Disease Drugs Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Parkinsons Disease Drugs Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Parkinsons Disease Drugs Sales (K Units) by Type (2018-2023) Table 51. Global Parkinsons Disease Drugs Sales (K Units) by Type (2024-2029) Table 52. Global Parkinsons Disease Drugs Sales Market Share by Type (2018-2023) Table 53. Global Parkinsons Disease Drugs Sales Market Share by Type (2024-2029) Table 54. Global Parkinsons Disease Drugs Revenue (US$ Million) by Type (2018-2023) Table 55. Global Parkinsons Disease Drugs Revenue (US$ Million) by Type (2024-2029) Table 56. Global Parkinsons Disease Drugs Revenue Market Share by Type (2018-2023) Table 57. Global Parkinsons Disease Drugs Revenue Market Share by Type (2024-2029) Table 58. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2018-2023) Table 59. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2024-2029) Table 60. Global Parkinsons Disease Drugs Sales (K Units) by Application (2018-2023) Table 61. Global Parkinsons Disease Drugs Sales (K Units) by Application (2024-2029) Table 62. Global Parkinsons Disease Drugs Sales Market Share by Application (2018-2023) Table 63. Global Parkinsons Disease Drugs Sales Market Share by Application (2024-2029) Table 64. Global Parkinsons Disease Drugs Revenue (US$ Million) by Application (2018-2023) Table 65. Global Parkinsons Disease Drugs Revenue (US$ Million) by Application (2024-2029) Table 66. Global Parkinsons Disease Drugs Revenue Market Share by Application (2018-2023) Table 67. Global Parkinsons Disease Drugs Revenue Market Share by Application (2024-2029) Table 68. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2018-2023) Table 69. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2024-2029) Table 70. Johnson & Johnson Corporation Information Table 71. Johnson & Johnson Description and Business Overview Table 72. Johnson & Johnson Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 73. Johnson & Johnson Parkinsons Disease Drugs Product Table 74. Johnson & Johnson Recent Developments/Updates Table 75. Gilead Sciences Corporation Information Table 76. Gilead Sciences Description and Business Overview Table 77. Gilead Sciences Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 78. Gilead Sciences Parkinsons Disease Drugs Product Table 79. Gilead Sciences Recent Developments/Updates Table 80. Pacira Corporation Information Table 81. Pacira Description and Business Overview Table 82. Pacira Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 83. Pacira Parkinsons Disease Drugs Product Table 84. Pacira Recent Developments/Updates Table 85. Sun Pharmaceutical Corporation Information Table 86. Sun Pharmaceutical Description and Business Overview Table 87. Sun Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 88. Sun Pharmaceutical Parkinsons Disease Drugs Product Table 89. Sun Pharmaceutical Recent Developments/Updates Table 90. Luye Pharma Corporation Information Table 91. Luye Pharma Description and Business Overview Table 92. Luye Pharma Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 93. Luye Pharma Parkinsons Disease Drugs Product Table 94. Luye Pharma Recent Developments/Updates Table 95. Sigma-Tau Group Corporation Information Table 96. Sigma-Tau Group Description and Business Overview Table 97. Sigma-Tau Group Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 98. Sigma-Tau Group Parkinsons Disease Drugs Product Table 99. Sigma-Tau Group Recent Developments/Updates Table 100. Fudan-Zhangjiang Corporation Information Table 101. Fudan-Zhangjiang Description and Business Overview Table 102. Fudan-Zhangjiang Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 103. Fudan-Zhangjiang Parkinsons Disease Drugs Product Table 104. Fudan-Zhangjiang Recent Developments/Updates Table 105. Teva Pharmaceutical Corporation Information Table 106. Teva Pharmaceutical Description and Business Overview Table 107. Teva Pharmaceutical Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 108. Teva Pharmaceutical Parkinsons Disease Drugs Product Table 109. Teva Pharmaceutical Recent Developments/Updates Table 110. CSPC Corporation Information Table 111. CSPC Description and Business Overview Table 112. CSPC Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 113. CSPC Parkinsons Disease Drugs Product Table 114. CSPC Recent Developments/Updates Table 115. Novartis Corporation Information Table 116. Novartis Description and Business Overview Table 117. Novartis Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 118. Novartis Parkinsons Disease Drugs Product Table 119. Novartis Recent Developments/Updates Table 120. Kingond Pharm Corporation Information Table 121. Kingond Pharm Description and Business Overview Table 122. Kingond Pharm Parkinsons Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023) Table 123. Kingond Pharm Parkinsons Disease Drugs Product Table 124. Kingond Pharm Recent Developments/Updates Table 125. Key Raw Materials Lists Table 126. Raw Materials Key Suppliers Lists Table 127. Parkinsons Disease Drugs Distributors List Table 128. Parkinsons Disease Drugs Customers List Table 129. Parkinsons Disease Drugs Market Trends Table 130. Parkinsons Disease Drugs Market Drivers Table 131. Parkinsons Disease Drugs Market Challenges Table 132. Parkinsons Disease Drugs Market Restraints Table 133. Research Programs/Design for This Report Table 134. Key Data Information from Secondary Sources Table 135. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Parkinsons Disease Drugs Figure 2. Global Parkinsons Disease Drugs Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Parkinsons Disease Drugs Market Share by Type in 2022 & 2029 Figure 4. Clinical Product Picture Figure 5. Experiment Product Picture Figure 6. Global Parkinsons Disease Drugs Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 7. Global Parkinsons Disease Drugs Market Share by Application in 2022 & 2029 Figure 8. Treament Figure 9. Prevention Figure 10. Global Parkinsons Disease Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 11. Global Parkinsons Disease Drugs Market Size (2018-2029) & (US$ Million) Figure 12. Global Parkinsons Disease Drugs Sales (2018-2029) & (K Units) Figure 13. Global Parkinsons Disease Drugs Average Price (USD/Unit) & (2018-2029) Figure 14. Parkinsons Disease Drugs Report Years Considered Figure 15. Parkinsons Disease Drugs Sales Share by Manufacturers in 2022 Figure 16. Global Parkinsons Disease Drugs Revenue Share by Manufacturers in 2022 Figure 17. The Global 5 and 10 Largest Parkinsons Disease Drugs Players: Market Share by Revenue in 2022 Figure 18. Parkinsons Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 19. Global Parkinsons Disease Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 20. North America Parkinsons Disease Drugs Sales Market Share by Country (2018-2029) Figure 21. North America Parkinsons Disease Drugs Revenue Market Share by Country (2018-2029) Figure 22. U.S. Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 23. Canada Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 24. Europe Parkinsons Disease Drugs Sales Market Share by Country (2018-2029) Figure 25. Europe Parkinsons Disease Drugs Revenue Market Share by Country (2018-2029) Figure 26. Germany Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 27. France Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 28. U.K. Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 29. Italy Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 30. Russia Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 31. Asia Pacific Parkinsons Disease Drugs Sales Market Share by Region (2018-2029) Figure 32. Asia Pacific Parkinsons Disease Drugs Revenue Market Share by Region (2018-2029) Figure 33. China Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Japan Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 35. South Korea Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 36. India Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 37. Australia Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 38. Taiwan Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. Indonesia Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. Thailand Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. Malaysia Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Philippines Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Latin America Parkinsons Disease Drugs Sales Market Share by Country (2018-2029) Figure 44. Latin America Parkinsons Disease Drugs Revenue Market Share by Country (2018-2029) Figure 45. Mexico Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Brazil Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 47. Argentina Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 48. Middle East & Africa Parkinsons Disease Drugs Sales Market Share by Country (2018-2029) Figure 49. Middle East & Africa Parkinsons Disease Drugs Revenue Market Share by Country (2018-2029) Figure 50. Turkey Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Saudi Arabia Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 52. U.A.E Parkinsons Disease Drugs Revenue Growth Rate (2018-2029) & (US$ Million) Figure 53. Global Sales Market Share of Parkinsons Disease Drugs by Type (2018-2029) Figure 54. Global Revenue Market Share of Parkinsons Disease Drugs by Type (2018-2029) Figure 55. Global Parkinsons Disease Drugs Price (USD/Unit) by Type (2018-2029) Figure 56. Global Sales Market Share of Parkinsons Disease Drugs by Application (2018-2029) Figure 57. Global Revenue Market Share of Parkinsons Disease Drugs by Application (2018-2029) Figure 58. Global Parkinsons Disease Drugs Price (USD/Unit) by Application (2018-2029) Figure 59. Parkinsons Disease Drugs Value Chain Figure 60. Parkinsons Disease Drugs Production Process Figure 61. Channels of Distribution (Direct Vs Distribution) Figure 62. Distributors Profiles Figure 63. Bottom-up and Top-down Approaches for This Report Figure 64. Data Triangulation Figure 65. Key Executives Interviewed

Johnson & Johnson Gilead Sciences Pacira Sun Pharmaceutical Luye Pharma Sigma-Tau Group Fudan-Zhangjiang Teva Pharmaceutical CSPC Novartis Kingond Pharm